Shares in Swedish medical technology firm Getinge soared more than 12% on Friday, 17 July 2026, after the company reported better-than-expected second-quarter results, driven by tariff refunds and price increases. The stock was among the top performers in the European healthcare sector, closing at its highest level in several months.
Getinge reported that it had received refunds on certain tariffs that had previously weighed on its supply chain costs, while simultaneously pushing through price hikes across its product portfolio. The combination helped lift operating margins more than analysts had anticipated, prompting several brokerages to upgrade their price targets for the stock.
The positive read-across boosted UK-listed medical device and healthcare stocks. Smith & Nephew rose 1.8%, while ConvaTec added 1.5%. The FTSE 100 index edged up 0.3% on the day, with the healthcare sector providing a significant tailwind. The FTSE 250, which has a higher weighting of mid-cap healthcare firms, gained 0.4%.
Analysts at Jefferies commented that Getinge's results suggest pricing power remains robust across the medical technology space, despite ongoing cost pressures. 'The ability to pass on higher costs and secure tariff relief is a positive signal for the broader sector,' they noted in a research note. However, they cautioned that not all firms may be able to replicate Getinge's success, given differences in product mix and geographic exposure.
For UK investors and pension holders with exposure to healthcare funds or ETFs, the news provides some reassurance. The sector has been under pressure in recent months due to rising input costs and regulatory uncertainty. Getinge's strong quarter may indicate that pricing strategies are beginning to offset these headwinds, though individual company performance will vary.